Financial Disclosure

Beijing – – September 29, 2026 -- iHuman Inc. (NYSE: IH) reported a second-quarter net loss of RMB17.5 million (US$2.6 million), reversing a net income of RMB30.7 million in the same period last year, as revenues fell 17.8% to RMB173.4 million (US$25.6 million) from RMB210.9 million.

Revenue Decline Tied to Falling Birth Rates and Cautious Spending

The company attributed the drop directly to China's declining newborn population and more conservative consumer spending. Average total monthly active users fell to 20.72 million from 23.97 million a year earlier, a 13.6% decrease also linked to the demographic downturn.

Boston – September 29, 2026 -- Atomic, an AI-native supply chain planning platform, closed a $12.5 million Series A led by Klass Capital and Madrona to expand from planning software into a full operating control system for physical goods companies.

Atomic already automates 90% of purchasing for DoorDash's DashMart network

DoorDash's DashMart convenience and essentials business migrated to Atomic in roughly three months with zero business disruption and feature parity with legacy systems. The platform now automates 90% of purchasing decisions across hundreds of DashMart sites. Nick Palefsky, Director of New Business Verticals at DoorDash, said Atomic lets the company apply years of operating judgment across its network daily, including how to sequence primary and backup suppliers.

New York – – September 29, 2026 -- Deloitte analysis projects that shifting U.S. healthcare from reactive treatment to proactive, life-stage-aware care could generate $527 billion in additional potential spending on women's health by 2030 compared with a baseline trajectory.

Deloitte models a 20-year health span gain from earlier intervention

Under a prevention and improved disease-management scenario, Deloitte's actuarial Future of Health model — built on five years of medical and pharmacy claims data from nearly 60 million lives — estimates women's health span could increase by up to 20 years in the long run. The firm's report, "How a $527 billion growth opportunity in women's health can improve health outcomes," compares a baseline 2030 spending trajectory against a scenario emphasizing earlier detection and management across 22 disease states.

Washington, D.C. – September 29, 2026 -- LUNGevity Foundation has committed $2 million to fund two three-year clinical research projects aimed at improving the diagnosis of indeterminate pulmonary nodules (IPNs), a condition affecting more than 1.5 million Americans annually after routine chest CT scans.

The funding, awarded through the 2026 RTFCCR/LUNGevity Early Detection Award in partnership with the Rising Tide Foundation for Clinical Cancer Research (RTFCCR), targets a diagnostic gap that currently forces many patients into unnecessary invasive procedures or prolonged uncertainty when non-invasive tools fail to determine whether a lung nodule is benign or malignant.

Espoo – September 29, 2026 -- Valmet Oyj's Board of Directors has confirmed that the second instalment of its 2025 dividend, EUR 0.67 per share, will be paid on October 7, 2026.

Shareholders on record October 1 qualify for payout

The dividend will go to shareholders registered in Valmet's shareholders' register held by Euroclear Finland Oy on the record date of October 1, 2026.

Total 2025 dividend reaches EUR 1.35 per share in two tranches

Valmet's Annual General Meeting in 2026 approved a total dividend of EUR 1.35 per share for the 2025 financial year, split into two instalments. The first tranche of EUR 0.68 per share was paid on April 9, 2026.

Payout ratio hits 89%, well above policy floor

Valmet's dividend policy commits to distributing at least 50% of the period's profit as dividend. The 2025 payout ratio stands at 89%, substantially exceeding that minimum threshold.

Oslo, Norway – September 29, 2026 -- Nel ASA has secured a purchase order worth approximately USD 12 million from Collins Aerospace for PEM electrolyser stacks destined for US Navy submarine life-support systems. The order was placed through Nel Hydrogen US, a subsidiary of the Oslo-listed hydrogen technology company (OSE: NEL).

Collins Aerospace extends long-running defence procurement with Nel

The stacks will generate oxygen for submarine crews, an application where equipment failure carries direct safety consequences. Nel's Chief Commercial Officer, Todd Cartwright, said the order extends a long-standing cooperation with Collins Aerospace built around reliable oxygen generation for demanding submarine applications, and confirms the continued relevance of the company's PEM technology and manufacturing capabilities.

Amsterdam – September 29, 2026 -- Nearly $300 million in European spend has now moved through Arkestro's predictive procurement platform, with regional volume growing 93% year over year, the company announced at DPW Amsterdam 2026.

Baseline spend in international procurement events surged 330% from 2024 to 2025

Arkestro projects a further 47% increase in 2026 as existing global customers extend the platform into additional European teams, categories and supplier networks. The company said the growth reflects enterprises seeking faster procurement decisions amid market volatility.

Platform users across Europe grew 78% year over year

Arkestro's buyer and supplier interactions now span 34 countries, and customers running completed European procurement events have generated approximately 10% average savings, the company said.

Irvine, Calif. – – September 29, 2026 -- Performance Brokerage Services has brokered the sale of Genesis of Glenview, Illinois, to Joe Ghaben, adding a fifth franchise point to the Chicago-area Ghaben Auto Group.

Ghaben Auto Group expands Chicago footprint with Genesis acquisition

Ghaben Auto Group, founded in 2004, already operates Volkswagen of Oak Lawn, Volkswagen of Orland Park, and the two-location Ultimo Motors luxury pre-owned brand in Northbrook and Westmont. The Genesis acquisition marks the group's entry into the Genesis franchise network.

Dealership will relocate to a new facility on Patriot Boulevard

Genesis of Glenview will retain its name but move operations to a newly built facility at 2929 Patriot Boulevard in Glenview, Illinois.

Shanghai – – September 29, 2026 -- Hengrui Pharma has licensed its investigational obesity and diabetes drug HRS-1596 to Novo Nordisk in a deal worth up to 2.6 billion US dollars, including a 300 million dollar upfront payment.

Novo secures global rights excluding Greater China

Under the agreement, Novo obtains exclusive rights to develop, manufacture and commercialise HRS-1596 worldwide, excluding the Chinese mainland, Hong Kong SAR, Macao SAR and Taiwan Region. Hengrui Pharma retains eligibility for royalties on net sales of the drug within Novo's licensed territory, on top of the milestone-based payments tied to development, regulatory and commercial targets.

Shanghai – – September 29, 2026 -- Zoomlion Heavy Industry Science & Technology Co., Ltd. has signed a US$300 million portfolio credit insurance policy alongside an initial US$50 million non-recourse factoring agreement, creating a tiered financing structure for the company's overseas installment receivables. The deals were finalized at the Zoomlion 2026 Global Financial Partners Summit in Shanghai on September 11.

New framework converts overseas receivables into standardized, investment-grade assets

Developed over six months with international insurers and financial institutions, the arrangement lets overseas installment receivables covered by the credit insurance policy be factored with an overseas bank on a non-recourse basis. The structure replaces transaction-by-transaction handling of overseas receivables with a scalable, replicable financing model.